MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Exagen EV/EBITDA Ratio 2011-2026 | XGN
Annual EV/EBITDA Ratio Exagen
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.2 | -13.3 | -3.94 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.2 | -13.3 | -6.47 |
EV/EBITDA Ratio of other stocks in the Diagnostics research industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
0.387 | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
28.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
-43.6 | $ 13.65 | -0.44 % | $ 99.4 M |  Israel |
 |
Aspira Women's Health
AWH
|
-2.63 | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
26.4 | $ 8.87 | 2.9 % | $ 591 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-73.4 | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
22 | $ 151.97 | -2.34 % | $ 7.53 B | USA |
 |
Castle Biosciences
CSTL
|
-21.2 | $ 25.83 | 1.06 % | $ 717 M | USA |
 |
CareDx, Inc
CDNA
|
-100 | $ 17.32 | 1.82 % | $ 923 M | USA |
 |
DexCom
DXCM
|
39.5 | $ 66.34 | 3.27 % | $ 25.9 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-5.56 | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-20.8 | $ 103.85 | 0.27 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
-3.52 | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-13.6 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-2.67 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-2.67 | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
2.58 | $ 14.95 | 1.22 % | $ 452 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
20.8 | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
-4.25 | $ 17.29 | -3.3 % | $ 2.24 B | USA |
 |
Guardant Health
GH
|
-28.8 | $ 87.18 | 1.98 % | $ 10.9 B | USA |
 |
Anixa Biosciences
ANIX
|
-2.25 | $ 2.84 | 0.35 % | $ 92.2 K | USA |
 |
Danaher Corporation
DHR
|
20.1 | $ 191.39 | 2.17 % | $ 136 B | USA |
 |
Biocept
BIOC
|
-26.9 | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
141 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-1.42 | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
38 | $ 97.61 | -0.73 % | $ 8.05 B |  Irlanda |
 |
IQVIA Holdings
IQV
|
24.1 | $ 164.89 | 0.1 % | $ 28.3 B | USA |
 |
Illumina
ILMN
|
70.5 | $ 119.28 | 0.29 % | $ 19 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.51 | $ 198.94 | -0.38 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
13.2 | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
27.4 | $ 111.83 | 0.28 % | $ 34 B | USA |
 |
BioNano Genomics
BNGO
|
-7.71 | $ 1.11 | - | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
-1.05 | $ 8.42 | -6.44 % | $ 239 M | Israel |
 |
Lantheus Holdings
LNTH
|
-187 | $ 78.5 | -1.25 % | $ 5.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
-1.23 | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-0.674 | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
3.62 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
30.7 | $ 453.64 | 0.72 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
0.351 | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
827 | $ 1 198.71 | 2.13 % | $ 24.7 B |  Schweiz |
 |
Celcuity
CELC
|
-2.38 | $ 114.9 | 0.6 % | $ 4.53 B | USA |
 |
DermTech
DMTK
|
-2.44 | - | -11.32 % | $ 2.94 M | USA |
 |
Neogen Corporation
NEOG
|
40.3 | $ 9.11 | 0.22 % | $ 1.98 B | USA |
 |
National Research Corporation
NRC
|
21 | $ 17.4 | 5.33 % | $ 389 M | USA |
 |
NeoGenomics
NEO
|
-33.5 | $ 8.24 | 4.57 % | $ 1.06 B | USA |
 |
Invitae Corporation
NVTA
|
-10.7 | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
58.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
-19.5 | $ 197.68 | 5.23 % | $ 19.5 B | USA |
 |
OPKO Health
OPK
|
25.9 | $ 1.19 | - | $ 826 M | USA |
 |
Pacific Biosciences of California
PACB
|
-23.8 | $ 1.36 | 2.26 % | $ 408 M | USA |